StockAxis

Divi's Laboratories Ltd

Quarterly Result - Q2FY23

Divi's Laboratories Ltd

Pharmaceuticals & Drugs - API

Current

CMP
Rs. 3336.25
Rating:
Hold
November 07, 2022

Previous

Rating:
Hold

Stock Info

BSE
532488
NSE
DIVISLAB
Bloomberg
DIVI:IN
Reuters
DIVI.NS
Sector
Pharmaceuticals & Drugs - API
Face Value (Rs)
2
Equity Capital (Rs cr)
53
Mkt Cap (Rs cr)
87733.38
52w H/L (Rs)
5093.25 - 3365.55
Avg Daily Vol (BSE+NSE)
227,592

Shareholding Pattern

(as on 30-Sep)
%
Promoter
51.94
FIIs
15.40
DIIs
20.75
Public & Others
11.91
Source: Ace equity, StockAxis Research

Price performance

Return (%)
1m
3m
12m
Absolute
-8.60
-13.28
-30.27
Sensex
5.14
3.96
1.06
Source: Ace equity, StockAxis Research

Indexed Stock Performance

Divi's Laboratories Ltd Sensex
Divi's Laboratories Ltd
Source: Ace equity, StockAxis Research

Financial Highlights:

Particulars (Rs. in Crores) Q2FY23 Q2FY22 YoY (%) Q1FY23 QoQ (%)
Revenue from Operations 1855.00 1987.51 -7.00% 2255.00 -18.00%
EBITDA 621.51 818.07 -24.00% 847.00 -27.00%
EBITDA Margin (%) 34.00% 41.00% 37.56%
Profit After Tax 493.99 606.46 -19.00% 702.00 -30.00%
Earnings Per Share (Rs.) 18.60 22.84 26.00

Source: Company Filings; StockAxis Research

Quarterly result highlights Q2FY23
Divis Labs posted weak earnings for the quarter ended Q2FY23, mainly because of the slowdown in custom synthesis and erosion in margins that dragged the overall performance for the company. Consolidated revenues de-grew 7% to Rs.1855 cr on a YoY basis.

The custom synthesis segment revenue (43% of revenues) dropped by 26% YoY to Rs.797 cr YoY due to reduced sales of Molnupiravir on a high base of COVID sales. Nutraceuticals sales fell 3% YoY at Rs.163 cr. Generic API business, however, posted a growth of 20%.

EBITDA recorded at Rs.622 declined sharply due to lower revenues and elevated raw material costs. EBITDA Margins for the quarter stood at 34%, contracting sharply by 700 bps on a YoY basis as it was impacted by the change in product mix, higher other expenses and negative operating leverage. The company has been impacted by higher prices of solvents (toluene) along with higher energy costs resulting into weak operational show by the company.

Due to lower revenues and weak operational performance by the company, PAT also declined by 19% to Rs.494 cr on a YoY basis.

Conference Call Highlights

  • Divis’ witnessed higher energy (power and fuel) cost and transport cost in this quarter. Some stability is being seen in cost of raw materials.
  • Company got several opportunities in last six months in Custom Synthesis segment which are mainly in Phase 2 and 3; expects some of them to commercialize in near term. On custom synthesis, management indicated that US and EU do not have enough capacities to produce the newer off-patent drugs, which will provide immense opportunity for Indian drug makers in the coming years.
  • Company has filed multiple DMFs in regulated markets in generic API segment and expects most of them to be commercialized as products goes off patent over FY23-25E which has total market size of US$20bn.
  • Company continue to experience price increase in RM and solvent prices along with higher logistic and energy cost. Divi’s has reduced its raw material dependency on China by 20% compared to H1FY22.
  • No further progress on Kakinada plant, as company is still waiting for government clearance.
  • Overall capacity utilization is ~80-83%.
  • The backward integration initiative taken by DIVI over past 15-18 months has helped DIVIs to protect margin in the Sartans segment, despite increase in raw material prices on account of COVID led restrictions in China. Particularly, for Sartans, DIVI is not only gaining traction in existing products, but it also intends to add more molecules in this category to supply.

Outlook & valuation

Divis growth prospects across businesses remain positive and will propel growth in the future. Given its established capabilities, backward integration, quality focus, and scale benefits, as well as major capacity expansion plans going on stream, the company is well-positioned to meet increasing demand from global big pharma companies. Divi’s remains preferred play on Indian CRAMS and API given its strong execution track record.

At CMP of Rs.3414 as on November 07, 2022, the stock is trading at 26x FY25E and we maintain hold on the stock.

Quarterly Financials

Particulars (Rs. in Crores) Q2FY23 Q2FY22 YoY (%) Q1FY23 QoQ (%)
Revenue from Operations 1855.00 1987.51 -7.00% 2255.00 -18.00%
COGS 674.62 654.83 812.00
Gross Profit 1180.38 1332.68 -11.00% 1443.00 -18.00%
Gross Margin (%) 64.00% 67.00% 64.00%
Employee Benefit Expenses 232.12 223.98 246.00
Other Expenses 326.75 290.63 349.00
EBITDA 621.51 818.07 -24.00% 847.00 -27.00%
EBITDA Margin (%) 34.00% 41.00% 37.56%
Depreciation 85.73 77.35 84.00
EBIT 535.78 740.72 -28.00% 763.00 -30.00%
EBIT Margin (%) 29.00% 37.00% 33.84%
Finance Cost 0.17 0.21 0.00
Other Income 80.00 19.11 88.00
Profit Before Tax 615.61 759.62 -19.00% 851.00 -28.00%
Tax 121.62 153.16 149.00
Effective Tax Rate (%) 20.00% 20.00% 18.00%
Profit After Tax 493.99 606.46 -19.00% 702.00 -30.00%
PAT Margin (%) 27.00% 31.00% 31.14%
Earnings Per Share (Rs.) 18.60 22.84 26.00

Source: Company Filings; StockAxis Research

Consolidated Financial statements

Profit & Loss statement

Year End March (Rs. in Crores) 2021 2022 2023E 2024E 2025E
Net Sales 6969.40 8959.80 8707.30 10057.50 11350.00
Growth % 29.20% 28.60% -2.80% 15.50% 12.90%
Expenditure
Material Cost 2376.70 2967.50 2960.50 3218.40 3632.00
Employee Cost 825.80 946.20 1131.90 1206.90 1362.00
Other Expenses 905.90 1163.90 1219.00 1377.90 12.90%
EBITDA 2861.10 3882.30 3395.80 4254.30 4891.90
Growth % 56.90% 35.70% -12.50% 25.30% 15.00%
EBITDA Margin 41.10% 43.30% 39.00% 42.30% 43.00%
Depreciation & Amortization 255.60 311.50 324.00 331.00 356.00
EBIT 2605.50 3570.80 3071.80 3923.30 4535.90
EBIT Margin % 37.40% 39.90% 35.30% 39.00% 40.00%
Other Income 62.70 113.80 135.00 127.00 145.00
Interest & Finance Charges 2.10 0.80 1.80 2.20 3.20
Profit Before Tax - Before Exceptional 2666.00 3683.80 3205.00 4048.10 4677.70
Profit Before Tax 2666.00 3683.80 3205.00 4048.10 15.60%
Tax Expense 681.80 724.00 806.70 1018.90 1178.80
Effective Tax rate 25.60% 19.70% 25.20% 25.20% 25.20%
Net Profit 1984.30 2959.80 2398.30 3029.20 3498.90
Growth % 44.20% 49.20% -19.00% 26.30% 15.50%
Net Profit Margin 28.50% 33.00% 27.50% 30.10% 31.00%
Consolidated Net Profit 1984.30 2959.80 2398.30 3029.20 3498.90
Growth % 44.20% 49.20% -19.00% 26.30% 15.50%

Balance Sheet

As of March (Rs. in Crores) 2021 2022 2023E 2024E 2025E
Share Capital 53.10 53.10 53.10 53.10 53.10
Total Reserves 9241.50 11675.10 13542.50 16040.80 19008.80
Shareholders' Funds 9294.60 11728.20 13595.60 16093.90 19061.90
Non Current Liabilities
Long Term Burrowing - - 41.00 51.20 63.40
Deferred Tax Assets / Liabilities 334.80 421.40 421.40 421.40 421.40
Long Term Provisions 25.40 26.70 26.70 26.70 26.70
Current Liabilities -
Short Term Borrowings 0.40 0.40 0.40 0.40 0.40
Trade Payables 763.20 796.00 847.10 899.70 1026.40
Other Current Liabilities 340.40 330.30 330.30 330.30 330.30
Short Term Provisions 624.40 68.00 68.00 68.00 68.00
Total Equity & Liabilities 11386.90 13373.80 15333.30 17894.40 21001.30
Assets -
Net Block 3703.90 4080.40 4381.40 4750.40 5194.40
Non Current Investments 0.00 0.00 0.00 0.00 0.00
Long Term Loans & Advances 172.60 173.60 173.60 173.60 173.60
Current Assets
Currents Investments - - - - -
Inventories 2145.20 2828.60 2783.20 2956.10 3372.40
Sundry Debtors 1676.50 2423.90 2541.20 2699.00 3079.20
Cash and Bank 2156.00 2818.90 4641.70 6503.10 8368.70
Short Term Loans and Advances 749.90 217.00 217.00 217.00 217.00
Total Assets 11386.90 13373.80 15333.20 17894.50 21001.40

Cash Flow Statement

Year End March (Rs. in Crores) 2021 2022 2023E 2024E 2025E
Profit After Tax 1984.30 2959.80 2398.30 3029.20 3498.90
Depreciation 255.60 311.50 324.00 331.00 356.00
Changes in Working Capital -264.10 -1272.30 -20.80 -278.20 -669.70
Cash From Operating Activities 1946.90 1999.00 2701.50 3082.00 3185.10
Purchase of Fixed Assets -910.20 -713.00 -600.00 -700.00 -800.00
Free Cash Flows 1036.70 1286.00 2101.50 2382.00 2385.10
Cash Flow from Investing Activities 75.10 -713.00 1253.10 -699.90 -799.90
Increase / (Decrease) in Loan Funds - 37.80 3.20 10.20 11.20
Cash from Financing Activities -34.90 -493.10 -527.70 -520.70 -519.70
Net Cash Inflow / Outflow 1987.20 792.90 3426.90 1861.40 1865.50
Opening Cash & Cash Equivalents 43.20 2030.30 1214.80 4641.70 6503.10
Closing Cash & Cash Equivalent 2030.30 1214.80 4641.70 6503.10 8368.70

Key Ratios

Year End March 2021 2022 2023E 2024E 2025E
Basic EPS 74.80 111.50 90.30 114.10 131.80
Diluted EPS 74.80 111.50 90.30 114.10 131.80
Cash EPS (Rs) 84.40 123.20 102.60 126.60 145.20
DPS 20.00 20.00 20.00 20.00 20.00
Book value (Rs/share) 350.10 441.80 512.20 606.30 718.10
ROCE (%) Post Tax 23.90% 28.20% 18.90% 20.40% 19.90%
ROE (%) 21.30% 25.20% 17.60% 18.80% 18.40%
Inventory Days 105.00 130.00 115.00 115.00 115.00
Receivable Days 80.90 110.00 105.00 105.00 105.00
Payable Days 35.50 45.00 35.00 35.00 35.00
PE 48.50 32.80 37.80 29.90 25.90
P/BV 10.30 8.30 6.70 5.60 4.80
EV/EBITDA 32.90 24.30 25.30 19.80 16.80
Dividend Yield (%) 0.60% 0.50% 0.60% 0.60% 0.60%
P/Sales 13.80 10.80 10.40 9.00 8.00
Net debt/Equity - - - - -
Net Debt/ EBITDA -0.80 -0.70 -1.40 -1.50 -1.70